Premium
Synthesis of deuterated‐BCX‐34 (peldesine)
Author(s) -
Hutchison Tracy L.,
Morris Philip E.
Publication year - 1999
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/(sici)1099-1344(19991230)42:13<1235::aid-jlcr279>3.0.co;2-q
Subject(s) - chemistry , deuterium , purine nucleoside phosphorylase , chemical synthesis , stereochemistry , nucleoside analogue , nucleoside , combinatorial chemistry , purine , in vitro , organic chemistry , enzyme , biochemistry , physics , quantum mechanics
BCX‐34 (peldesine) is a novel purine nucleoside phosphorylase inhibitor that is in human clinical trials for the treatment of T‐cell cancers and for HIV infected patients. In support of our BCX‐34 clinical program, a mass spectrometric assay has been developed utilizing a deuterated‐BCX‐34 analog as an internal standard. The synthesis of tetra‐deuterated‐BCX‐34 (peldesine) from ethyl nicotinate (2,4,5,6‐[ 2 H] 4 ) is described in this report. Copyright © 1999 John Wiley & Sons, Ltd.